Wave Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
At the midpoint of 2026, the platform is advancing differentiated RNA therapies, with WVE-007 showing strong body composition results and moving into phase II-A for obesity. RNA editing programs for AATD and PNPLA3 are progressing, with regulatory and clinical milestones expected this year.
-
Key programs in obesity, AATD, and liver disease are advancing, with INHBE studies set to launch and focus shifting to body composition as a regulatory endpoint. Recent data show strong differentiation in fat loss and muscle preservation, and regulatory feedback for AATD is expected mid-year.
-
Key advances include progress in siRNA and RNA editing platforms, with promising clinical data for obesity and AATD. Monthly dosing regimens and biomarker-driven regulatory strategies are being pursued, while new studies target high BMI and cardiometabolic endpoints.
-
RestorAATion-2 phase I/II data show WVE-006 achieves robust, durable Z-AAT reduction and wild-type M-AAT restoration, mimicking the protective MZ phenotype in PiZZ AATD. The therapy is safe, well-tolerated, and supports convenient monthly dosing, with dynamic AAT responses during inflammation.
-
Lead programs for obesity and AATD advanced with strong clinical data, including significant visceral fat loss and dynamic AAT restoration. Revenue surged year-over-year, cash runway extends into 2028, and multiple pivotal trials and regulatory milestones are expected in 2026.
-
Interim phase I data show WVE-007 produces significant, durable reductions in visceral and total fat with muscle preservation and a favorable safety profile in overweight or obese individuals. Phase II/a will target higher BMI populations to demonstrate greater efficacy and inform regulatory and commercial strategy.
-
The discussion highlighted advances in oligonucleotide and RNA editing therapies, with clinical data showing promising fat loss and muscle preservation in obesity, and robust protein correction in alpha-1 antitrypsin deficiency. Upcoming studies will target higher BMI populations and explore broader indications, supported by scalable manufacturing and innovative modalities.
-
The conference highlighted rapid advances in RNA chemistry, with lead obesity candidate WVE-007 showing durable fat loss and muscle preservation, differentiating it from GLP-1s. Strategic focus includes expanding clinical studies in obesity and RNA editing, with multiple data milestones expected in 2024.
Fiscal Year 2025
-
2025 saw strong clinical progress in obesity and AATD, with robust fat loss and muscle preservation in early WVE-007 data and significant RNA editing advances. Revenue declined due to the end of the Takeda collaboration, but cash reserves remain strong, supporting operations into 2028.
-
INLIGHT phase I interim data show WVE-007 achieves significant visceral and total fat reduction with muscle preservation after a single dose in overweight adults, matching or exceeding GLP-1s on fat loss but with a superior safety and dosing profile. Phase II studies in broader populations and maintenance settings are planned.
-
The conference highlighted progress in RNA-based therapies, with a focus on inhibin E for obesity and RNA editing for AATD. Key data readouts are expected in Q4 2025 and 2026, supporting once-yearly dosing and expansion into new genetic targets.
-
The conference highlighted advances in RNA medicines, including a first-in-human RNA editing program for Alpha-1 Antitrypsin Deficiency and a differentiated obesity therapy targeting INHBE. Both programs show strong clinical promise, with durable effects and clear regulatory strategies.
-
Q3 2025 saw increased revenue and narrowed net loss, driven by GSK collaboration and pipeline progress. Clinical programs in obesity, AATD, DMD, and HD advanced, with key data readouts and regulatory submissions expected in 2026. Cash runway extends into Q2 2027.
-
Multiple RNA editing and siRNA programs are advancing, with WVE-006 and WVE-007 showing strong clinical progress and WVE-008 set for clinical entry. Platform innovations enhance potency and durability, targeting large unmet needs in liver and metabolic diseases.
-
Panelists highlighted rapid clinical progress in ADAR RNA editing, with human data confirming effective mutation correction and durable protein restoration in AATD. The field is expanding to new targets and indications, leveraging platform innovations and robust preclinical-to-clinical translation.
-
A novel GalNAc-conjugated siRNA therapy targeting INHBE shows promise for sustainable fat loss with muscle preservation, offering a differentiated mechanism from GLP-1s. Early clinical data indicate strong safety, target engagement, and potential for infrequent dosing, with pivotal results expected in Q4.
-
The conference highlighted differentiated RNA therapeutic programs, including a novel siRNA for obesity with direct fat-targeting, an RNA editing approach for AATD showing strong efficacy, and a robust pipeline with upcoming clinical milestones. Key data readouts are expected in Q4 and Q1.
-
WVE-006 showed durable, efficient RNA editing in AATD patients, restoring protective M-AAT protein and reducing Z-AAT, with strong safety and dynamic response during acute events. Higher doses and less frequent dosing are being explored, with further data and clinical outcome studies planned in collaboration with GSK.
-
Advanced RNA editing and siRNA programs showed strong clinical progress, with key data readouts for AATD and obesity expected in late 2025 and early 2026. Revenue declined year-over-year, but cash reserves are projected to fund operations into 2027.
-
Key updates include advancing RNA editing in AATD with new multi-dose data expected, progress in obesity with Inhibit-E phase 1 results due this year, and regulatory momentum in DMD and Huntington’s programs. Strategic partnerships and milestone opportunities remain strong.
-
Q1 2025 saw pipeline advances in obesity, AATD, DMD, and Huntington's, with key clinical milestones achieved and regulatory alignment for accelerated approval. Revenue declined year-over-year, expenses rose, and cash is expected to fund operations into 2027.
-
The 48-week FORWARD-53 phase II study of WVE-N531 in DMD showed robust dystrophin restoration, significant improvements in muscle health and function, and a strong safety profile. Statistically significant gains in Time-to-Rise and NSAA, along with reduced fibrosis and inflammation, support N531's best-in-class potential.
-
Major advances in RNA editing and siRNA platforms have enabled new clinical programs in obesity, alpha-1 antitrypsin deficiency, DMD, and Huntington’s disease, with key data readouts and regulatory milestones expected in 2025. The pipeline targets over 100 million patients and is supported by a strong financial position.
Fiscal Year 2024
-
Strong clinical progress in 2024 included first-in-human RNA editing, positive data in AATD, DMD, and HD, and the launch of an obesity program. Revenue rose sharply in Q4, cash runway extends into 2027, and key data readouts are expected in 2025.
-
Panelists discussed diverse DMD treatment strategies, including RNA medicines, gene therapy, and corticosteroids, highlighting strong early data, upcoming clinical milestones, and a collaborative regulatory environment. Advances in delivery technology and global market strategies were emphasized.
-
The conference highlighted advances in oligonucleotide chemistry, positive clinical data in AATD, HD, and DMD, and a strong focus on genetically validated cardiometabolic targets. Key 2025 milestones include Inhibin E clinical trials, multi-dose AATD data, and DMD 48-week results.
-
The conference highlighted advances in RNA medicines, with late-stage progress in Huntington's and DMD, first-in-human RNA editing data for AATD, and a differentiated siRNA obesity program. Key milestones include IND filings, pivotal data readouts, and strong cash runway into 2027.
-
Delivered positive clinical data in AATD, DMD, and HD, advanced multiple programs toward key 2025 milestones, and strengthened financials with a $310.9M cash position and extended runway into 2027. Regulatory engagement supports potential accelerated approvals.
-
Recent clinical successes in RNA editing and allele-selective silencing have validated the platform's modular chemistry and accelerated pipeline, with WVE-007 and WVE-006 showing best-in-class preclinical and clinical results. New RNA editing programs target major unmet needs in liver and cardiovascular diseases, supported by strong human genetics and AI-driven discovery.
-
Major 2024 milestones include first-in-human allele-specific silencing in Huntington's, strong interim DMD data with consistent dystrophin expression, and upcoming RNA editing proof-of-mechanism results. Obesity and editing programs advance, leveraging unique chemistry and efficient delivery.
-
Interim phase 2 results for WVE-N531 in DMD show mean 9% muscle-adjusted dystrophin, high consistency across patients, significant biomarker improvements, and a clean safety profile. Monthly dosing is supported, with final 48-week data and regulatory engagement expected in Q1 2025.
-
Q2 2024 saw strong clinical progress in HD, DMD, AATD, and obesity programs, with positive SELECT-HD results, advancing WVE-N531 and WVE-006, and robust preclinical data for WVE-007. Net loss increased to $32.9M, with $154M cash on hand, funding operations into Q4 2025.
-
SELECT-HD results show WVE-003 achieved potent, durable, and allele-selective reduction of mutant huntingtin, with preserved wild-type protein and favorable safety. Statistically significant correlation between mutant protein reduction and slowing of caudate atrophy supports potential for accelerated approval using imaging endpoints.
-
Major clinical milestones are expected in 2024, including data readouts for Huntington's disease, DMD, and alpha-1 antitrypsin deficiency. Platform advancements and strategic collaborations with GSK and Takeda support a robust pipeline and financial outlook.